1. Roche's risdiplam deal a relief for SMA rivals Biogen and Novartis--for now— AstraZeneca targets summer start for COVID-19 antibody trial — Keros Therapeutics raises $96M in upsized IPO — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Vacant Territories

Discussion in 'Kala Pharmaceuticals' started by anonymous, Jul 17, 2019 at 10:30 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    There are 4 open territories and 1 RSL opportunity. What’s going on with such a small sales force this early in launch? Anyone else nervous about job security? Seems way too soon to be getting rid of people.
     

  2. anonymous

    anonymous Guest

    Exactly what I came here to ask. Seems lately a lot of openings. Idk what's going on but seems odd not even a year in...
     
  3. anonymous

    anonymous Guest

    What I want to know is what happened to manager KW in TX....?
     
  4. anonymous

    anonymous Guest

    Heard he was shit canned
     
  5. anonymous

    anonymous Guest

    Obviously, but for what?
     
  6. anonymous

    anonymous Guest

    The gulf coast region is in last place, so they probably fired him for performance. They expect quick results, no excuses. It’s unsettling how it’s still early in launch and people are being fired.
     
  7. anonymous

    anonymous Guest



    Is KW taking the job at B+L?
     
  8. anonymous

    anonymous Guest

    Ridiculous... Changing habits takes time, this doesn't happen overnight just bc you show up with something new. Ask the people who sold Xiidra.
     
  9. anonymous

    anonymous Guest

    You can obviously tell that managers are getting heat. I flipped two accounts in the last week and mine is still up my ass.
     
  10. anonymous

    anonymous Guest

    Do they know that cataract surgery and LASIK lull in the summer? It will kick back in fall and winter, they need to stop freaking the fuck out.
     
  11. anonymous

    anonymous Guest

    Yep.....you can tell upper management has no eyecare experience. They don’t seem to get it.
     
  12. anonymous

    anonymous Guest

    It's seriously embarrassing for them, frustrating for the reps (and concerning). I left my last company bc of this BS, I really thought this was going to be different. Next they are going to implement call metrics and start making us check the box instead of focusing actually on the business. It's been 7 months, things don't happen overnight and it's summer where less people are getting cataract surgery. Chill the hell out!
     
  13. anonymous

    anonymous Guest

    it is all because of benchmarking and the market research completed a long time ago:

    -benchmarking-On earnings calls the analysts are asking about competitive launches. B+L had launched LotemaxSM and has thousands of RXs already. In comparison (especially because of the molecule) we are behind. Doesn’t matter that it is “summer” when another drug has much more volume and launched at the same time.

    Market research-in our own investor slide presentation it showed 47-49% interest from doctors to prescribe. Management took this number and ran with it for forecasting. In the end it was rolled into goals and now we are significantly behind. No territory has half the doctors prescribing even 1 Rx let alone half the market share!

    This is why the pressure is on us now.
     
  14. anonymous

    anonymous Guest

    Right. It’s a crazy number....47-49% in a crazy saturated market.
    What the analysts and market research don’t seem to take into account is all of the resources Bausch has to offer doctors. They have an antibiotic and an NSID to help negotiate with surgeons. For the doctors this is all about what have you done for me lately and what can you give me. Bausch has all 3, we only have a steroid.
     
  15. anonymous

    anonymous Guest

    Not to mention twice the people, name recognition, yes a full portfolio not to mention surgical (yes they are quid pro quoing with drops). Our full size samples also cannibalize some of the business.
     
  16. anonymous

    anonymous Guest

    Right. It’s a crazy number....47-49% in a saturated market.
    What the analysts and market research don’t seem to take into account is all of the resources Bausch has to offer doctors. They have an antibiotic and an NSAID to help negotiate with surgeons. For the doctors this is all about what have you done for me lately and what can you give me. Bausch has all 3, we only have a steroid.
     
  17. anonymous

    anonymous Guest

    The full size samples are killing us
     
  18. anonymous

    anonymous Guest

    Yes
     
  19. anonymous

    anonymous Guest

    This isn't fun anymore. When we first started being here was so much fun. Not even a year in and it's gone. More pressure than any job in pharma I've ever had.
     
  20. anonymous

    anonymous Guest

    God, I agree! The Boston meeting was like a lifetime ago. I was so excited to be here and was confident in my decision to leave my last company and come over here. Now it’s like a different place with ignorant forecasts and expectations. I have never felt stress like this in a pharma job, it feels like the pressure of medical device without the freedom. Lose/lose